NO20055884L - Asenanin for behandling av schizofreni hos en pasient med overvekt eller predisposisjon for overvekt - Google Patents

Asenanin for behandling av schizofreni hos en pasient med overvekt eller predisposisjon for overvekt

Info

Publication number
NO20055884L
NO20055884L NO20055884A NO20055884A NO20055884L NO 20055884 L NO20055884 L NO 20055884L NO 20055884 A NO20055884 A NO 20055884A NO 20055884 A NO20055884 A NO 20055884A NO 20055884 L NO20055884 L NO 20055884L
Authority
NO
Norway
Prior art keywords
patient
obesity
overweight
schizophrenia
asenanine
Prior art date
Application number
NO20055884A
Other languages
English (en)
Inventor
Jeroen Alphons Dorothe Tonnaer
Original Assignee
Organon Ireland Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Organon Ireland Ltd filed Critical Organon Ireland Ltd
Publication of NO20055884L publication Critical patent/NO20055884L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

Oppfinnelsen tilveiebringer metoder for behandling av schizofreni med et antipsykotisk middel administrert til en pasient med overvekt eller til en pasient som har vektøkning på grunn av et antipsykotisk middel eller til en pasient som trenger å bli beskyttet mot vektøkning på grunn av tilstedeværelse av risikofaktorer for en sykdom for hvilken overvekt også er en risikofaktor eller på grunn av tilstedeværelse av andre vektøkende faktorer ved anvendelse av asenapin for fremstilling av en medisin
NO20055884A 2003-06-12 2005-12-12 Asenanin for behandling av schizofreni hos en pasient med overvekt eller predisposisjon for overvekt NO20055884L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03101721 2003-06-12
PCT/EP2004/051069 WO2004110437A1 (en) 2003-06-12 2004-06-09 Asenapine for the treatment of schizophrenia in a patient with overweight or predisposition for overweight

Publications (1)

Publication Number Publication Date
NO20055884L true NO20055884L (no) 2006-01-03

Family

ID=33547705

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20055884A NO20055884L (no) 2003-06-12 2005-12-12 Asenanin for behandling av schizofreni hos en pasient med overvekt eller predisposisjon for overvekt

Country Status (25)

Country Link
US (1) US20060128688A1 (no)
EP (1) EP1635820B1 (no)
JP (1) JP2006527238A (no)
KR (1) KR20060020664A (no)
CN (1) CN1816335A (no)
AR (1) AR044675A1 (no)
AT (1) ATE395914T1 (no)
AU (1) AU2004246820B2 (no)
BR (1) BRPI0411237A (no)
CA (1) CA2528365A1 (no)
CY (1) CY1110366T1 (no)
DE (1) DE602004013966D1 (no)
DK (1) DK1635820T3 (no)
ES (1) ES2305829T3 (no)
HK (1) HK1084894A1 (no)
IL (1) IL172397A (no)
NO (1) NO20055884L (no)
NZ (1) NZ544018A (no)
PL (1) PL1635820T3 (no)
PT (1) PT1635820E (no)
RU (1) RU2352336C2 (no)
SI (1) SI1635820T1 (no)
TW (1) TWI327915B (no)
WO (1) WO2004110437A1 (no)
ZA (1) ZA200509904B (no)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006106135A1 (en) * 2005-04-07 2006-10-12 N.V. Organon Crystal form of asenapine maleate
US7741358B2 (en) 2005-04-14 2010-06-22 N.V. Organon Crystal form of asenapine maleate
CA3047451A1 (en) 2016-12-20 2018-06-28 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine
JP7149287B2 (ja) * 2016-12-20 2022-10-06 エルテーエス ローマン テラピー－ジステーメ アーゲー アセナピンおよびポリシロキサンまたはポリイソブチレンを含有する経皮治療システム
EP3644973B1 (en) 2017-06-26 2021-03-24 LTS LOHMANN Therapie-Systeme AG Transdermal therapeutic system containing asenapine and silicone acrylic hybrid polymer
AU2019291060B2 (en) 2018-06-20 2024-09-05 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine
WO2020106330A1 (en) * 2018-07-18 2020-05-28 Pillsy, Inc. Smart drug delivery and monitoring device, kit, and method of use for pill compounds
CA3158745A1 (en) 2019-12-11 2021-06-17 Corcept Therapeutics Incorporated Methods of treating antipsychotic-induced weight gain with miricorilant
RU2756614C1 (ru) * 2021-04-07 2021-10-04 Федеральное государственное бюджетное научное учреждение «Томский национальный исследовательский медицинский центр Российской академии наук» (Томский НИМЦ) Способ поддержки принятия врачебных решений выбора антипсихотической терапии у больных шизофренией с целью профилактики акатизии

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2182981C (en) * 1994-03-02 2006-10-17 Leonardus Petrus Carla Delbressine Sublingual or buccal pharmaceutical composition
US5496831A (en) * 1994-05-13 1996-03-05 The General Hospital Corporation Inhibition of insulin-induced adiposis
JP2004517112A (ja) * 2001-01-02 2004-06-10 ファルマシア・アンド・アップジョン・カンパニー 新規薬物コンビネーション

Also Published As

Publication number Publication date
RU2006101061A (ru) 2006-07-27
IL172397A0 (en) 2006-04-10
PL1635820T3 (pl) 2008-10-31
DE602004013966D1 (de) 2008-07-03
TWI327915B (en) 2010-08-01
TW200501946A (en) 2005-01-16
AU2004246820A1 (en) 2004-12-23
KR20060020664A (ko) 2006-03-06
EP1635820B1 (en) 2008-05-21
CA2528365A1 (en) 2004-12-23
CN1816335A (zh) 2006-08-09
NZ544018A (en) 2008-07-31
US20060128688A1 (en) 2006-06-15
ES2305829T3 (es) 2008-11-01
WO2004110437A1 (en) 2004-12-23
SI1635820T1 (sl) 2008-08-31
EP1635820A1 (en) 2006-03-22
CY1110366T1 (el) 2014-04-09
AU2004246820B2 (en) 2009-10-01
ZA200509904B (en) 2006-12-27
IL172397A (en) 2010-06-16
ATE395914T1 (de) 2008-06-15
JP2006527238A (ja) 2006-11-30
DK1635820T3 (da) 2008-09-08
PT1635820E (pt) 2008-06-17
AR044675A1 (es) 2005-09-21
HK1084894A1 (en) 2006-08-11
RU2352336C2 (ru) 2009-04-20
BRPI0411237A (pt) 2006-07-11

Similar Documents

Publication Publication Date Title
NO20055884L (no) Asenanin for behandling av schizofreni hos en pasient med overvekt eller predisposisjon for overvekt
WO2007053661A3 (en) Uses of anti-cd40 antibodies
NO20070247L (no) Amino-5,5-difenylimidazolonderivater for inhibisjon av beta-sekretase
CO6390109A2 (es) Inhibidores de syk de imidazopirazina
NO20074999L (no) Metode og preparat for behandling av perifere vaskulaere sykdommer
WO2009039397A3 (en) Substituted amides, methods of making, use thereof for the treatment of diseases such as cancer
UY32177A (es) Tratamiento de diabetes en pacientes con control glucémico insuficiente a pesar de la terapia con fármaco, oral o no, antidiabético
NO20065847L (no) Difenylimidazopyrimidiner og -imidazolaminer som inhibitorer av B-sekretase
SG170101A1 (en) 2-pyrazinone derivatives for the treatment of disease or condition in which inhibition of neutrophil elastase activity is beneficial.
EP2331095A4 (en) CYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND METHOD OF USE THEREOF
WO2010029089A3 (en) Combination therapy for the treatment of diabetes and related conditions
MA28935B1 (fr) Preparation et utilisation de derives de biphenyl-4-yl-carbonylamino-acide dans le traitement de l'obesite
AU2012286851A8 (en) Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
MA32611B1 (fr) Procedes de traitement de la thalassemie
DK1915620T3 (da) Diagnose, behandling og prævention af vaskulære sygdomme ved hjælp af IL-1alpha-autoantistoffer
NO20083036L (no) Anvendelse av benzofuserte heterocykliske sulfamidderivater for behandling av depresjon
NO20084749L (no) Organiske forbindelser og deres anvendelser
DK1973541T3 (da) Anvendelse af benzokondenserede heterocykliske sulfamidderivater til nedsættelse af lipid- og blodglucoseniveauer
ATE456955T1 (de) Verwendung von cyclodextrin zur behandlung und vorbeugung von entzündlichen bronchialerkrankungen
WO2009068659A3 (en) Novel disease treatment by predicting drug association
NO20083004L (no) Anvendelse av benzofuserte heterocykliske sulfamidderivater for behandling av stoffmisbrukavhengighet
BRPI0921097B8 (pt) composto ou seu sal farmaceuticamente aceitável, intermediário do composto, composição farmacêutica e uso do composto
WO2007023072A3 (en) Use of ambroxol for the treatment of rhinovirus infections
MA46268A (fr) Dérivés de 5-[2-(pyridin-2-ylamino)-1,3-thiazol-5-yl]-2,3-dihydro-1h-isoindol-1-one et leur utilisation en tant qu'inhibiteurs doubles de phosphatidylinositol 3-kinase delta & gamma
DE602007011434D1 (de) 1h-indol-5-ylpiperazin-1-ylmethanonderivate

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application